%0 Journal Article
%T From Myeloma to Plasma Cell Leukemia, Persistent Inequalities
%A Mamadou Wague Gueye
%A Nata Dieng
%A Maguette Ndoye
%A Mor Ngom
%A Sokhna Moumi Mback¨¦ Daff¨¦
%A Papa Silman Diawara
%A Macoura Gadji
%A Nd¨¨ye Mari¨¨me Diagne
%A B¨¦caye Fall
%J Open Journal of Blood Diseases
%P 133-140
%@ 2164-3199
%D 2023
%I Scientific Research Publishing
%R 10.4236/ojbd.2023.134015
%X Multiple myeloma (MM) is both a complex and
heterogeneous disease.<span style=\"font-family:;\" \"=\"\"> </span><span style=\"font-family:;\" \"=\"\">Cytogenetic and molecular abnormalities lead to
resistance to treatment and transformation to plasma cell leukemia,</span><span style=\"font-family:;\" \"=\"\"> </span><span style=\"font-family:;\" \"=\"\">which is defined by the presence in circulating
blood of plasma cells over 2 G/L, or more than 20% of leukocytes. It is an
uncommon hematological malignancy with a poor prognosis. Against this backdrop,
we report an observation of multiple myeloma transformed into plasma cell
leukemia diagnosed at the H&#244;pital Principal de Dakar (HPD) that occurred on a
64-year-old man with a history of thyroidectomy followed for multiple myeloma
presenting with Salmon et Durie stage IIIA and ISS stage I. Despite a marked
improvement in management strategy, myeloma remains an almost invariably
incurable disease. However, the development of genetic and molecular biomarkers
is necessary to improve its prognosis.</span>
%K Multiple Myeloma
%K Plasma Cells Leukemia
%K Personalized Medicine
%K Risk Stratification
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=129671